Clinical trial
Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
NCT02396628 is registered in ClinicalTrials.gov with Prof. Dr. Nikolas von Bubnoff as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)
- Lead sponsor
- Prof. Dr. Nikolas von Bubnoff
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 29, 2017
- Completion date
- November 15, 2019
- Enrollment
- 22 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.